184 related articles for article (PubMed ID: 34844974)
21. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
23. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
[TBL] [Abstract][Full Text] [Related]
24. Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer.
Manchanda R; Menon U
Int J Gynecol Cancer; 2018 Jan; 28(1):34-42. PubMed ID: 29252925
[TBL] [Abstract][Full Text] [Related]
25. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354
[TBL] [Abstract][Full Text] [Related]
26. Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer.
Sia TY; Maio A; Kemel YM; Arora KS; Gordhandas SB; Kahn RM; Salo-Mullen EE; Sheehan MA; Tejada PR; Bandlamudi C; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Tew WP; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; Chi DS; Latham AJ; Carlo MI; Murciano-Goroff YR; Will M; Walsh MF; Robson ME; Mandelker DL; Berger MF; Abu-Rustum NR; Brown CL; Offit K; Hamilton JG; Aghajanian C; Weigelt B; Stadler ZK; Liu YL
JCO Precis Oncol; 2023 Sep; 7():e2300137. PubMed ID: 37738546
[TBL] [Abstract][Full Text] [Related]
27. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma.
Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
[TBL] [Abstract][Full Text] [Related]
28. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
Pal Choudhury P; Brook MN; Hurson AN; Lee A; Mulder CV; Coulson P; Schoemaker MJ; Jones ME; Swerdlow AJ; Chatterjee N; Antoniou AC; Garcia-Closas M
Breast Cancer Res; 2021 Feb; 23(1):22. PubMed ID: 33588869
[TBL] [Abstract][Full Text] [Related]
29. Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition.
Hughes E; Wagner S; Pruss D; Bernhisel R; Probst B; Abkevich V; Simmons T; Hullinger B; Judkins T; Rosenthal E; Roa B; Domchek SM; Eng C; Garber J; Gary M; Klemp J; Mukherjee S; Offit K; Olopade OI; Vijai J; Weitzel JN; Whitworth P; Yehia L; Gordon O; Pederson H; Kurian A; Slavin TP; Gutin A; Lanchbury JS
JCO Precis Oncol; 2022 Nov; 6():e2200084. PubMed ID: 36331239
[TBL] [Abstract][Full Text] [Related]
30. Moderate-Risk Genes for Hereditary Ovarian Cancers Involved in the Homologous Recombination Repair Pathway.
Abe A; Imoto I; Ueki A; Nomura H; Kanao H
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233090
[TBL] [Abstract][Full Text] [Related]
31. A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.
Jervis S; Song H; Lee A; Dicks E; Harrington P; Baynes C; Manchanda R; Easton DF; Jacobs I; Pharoah PP; Antoniou AC
J Med Genet; 2015 Jul; 52(7):465-75. PubMed ID: 26025000
[TBL] [Abstract][Full Text] [Related]
32. The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study.
Evans DG; Brentnall A; Byers H; Harkness E; Stavrinos P; Howell A; ; Newman WG; Cuzick J
J Med Genet; 2017 Feb; 54(2):111-113. PubMed ID: 27794048
[TBL] [Abstract][Full Text] [Related]
33. Genetically predicted circulating protein biomarkers and ovarian cancer risk.
Considine DPC; Jia G; Shu X; Schildkraut JM; Pharoah PDP; Zheng W; Kar SP;
Gynecol Oncol; 2021 Feb; 160(2):506-513. PubMed ID: 33246661
[TBL] [Abstract][Full Text] [Related]
34. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.
DeVries AA; Dennis J; Tyrer JP; Peng PC; Coetzee SG; Reyes AL; Plummer JT; Davis BD; Chen SS; Dezem FS; Aben KKH; Anton-Culver H; Antonenkova NN; Beckmann MW; Beeghly-Fadiel A; Berchuck A; Bogdanova NV; Bogdanova-Markov N; Brenton JD; Butzow R; Campbell I; Chang-Claude J; Chenevix-Trench G; Cook LS; DeFazio A; Doherty JA; Dörk T; Eccles DM; Eliassen AH; Fasching PA; Fortner RT; Giles GG; Goode EL; Goodman MT; Gronwald J; ; ; Håkansson N; Hildebrandt MAT; Huff C; Huntsman DG; Jensen A; Kar S; Karlan BY; Khusnutdinova EK; Kiemeney LA; Kjaer SK; Kupryjanczyk J; Labrie M; Lambrechts D; Le ND; Lubiński J; May T; Menon U; Milne RL; Modugno F; Monteiro AN; Moysich KB; Odunsi K; Olsson H; Pearce CL; Pejovic T; Ramus SJ; Riboli E; Riggan MJ; Romieu I; Sandler DP; Schildkraut JM; Setiawan VW; Sieh W; Song H; Sutphen R; Terry KL; Thompson PJ; Titus L; Tworoger SS; Van Nieuwenhuysen E; Edwards DV; Webb PM; Wentzensen N; Whittemore AS; Wolk A; Wu AH; Ziogas A; Freedman ML; Lawrenson K; Pharoah PDP; Easton DF; Gayther SA; Jones MR
J Natl Cancer Inst; 2022 Nov; 114(11):1533-1544. PubMed ID: 36210504
[TBL] [Abstract][Full Text] [Related]
35. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract][Full Text] [Related]
36. Validation of the BOADICEA model in a prospective cohort of
Yang X; Mooij TM; Leslie G; Ficorella L; Andrieu N; Kast K; Singer CF; Jakubowska A; van Gils CH; Tan YY; Engel C; Adank MA; van Asperen CJ; Ausems MGEM; Berthet P; ; Collee MJ; Cook JA; Eason J; Spaendonck-Zwarts KYV; Evans DG; Gómez García EB; Hanson H; Izatt L; Kemp Z; Lalloo F; Lasset C; Lesueur F; Musgrave H; Nambot S; Noguès C; Oosterwijk JC; Stoppa-Lyonnet D; Tischkowitz M; Tripathi V; Wevers MR; Zhao E; van Leeuwen FE; Schmidt MK; Easton DF; Rookus MA; Antoniou AC
J Med Genet; 2024 Jun; ():. PubMed ID: 38834293
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel epithelial ovarian cancer loci in women of African ancestry.
Manichaikul A; Peres LC; Wang XQ; Barnard ME; Chyn D; Sheng X; Du Z; Tyrer J; Dennis J; Schwartz AG; Cote ML; Peters E; Moorman PG; Bondy M; Barnholtz-Sloan JS; Terry P; Alberg AJ; Bandera EV; Funkhouser E; Wu AH; Pearce CL; Pike M; Setiawan VW; Haiman CA; ; ; Palmer JR; LeMarchand L; Wilkens LR; Berchuck A; Doherty JA; Modugno F; Ness R; Moysich K; Karlan BY; Whittemore AS; McGuire V; Sieh W; Lawrenson K; Gayther S; Sellers TA; Pharoah P; Schildkraut JM;
Int J Cancer; 2020 Jun; 146(11):2987-2998. PubMed ID: 31469419
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
39. Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.
Girardi F; Barnes DR; Barrowdale D; Frost D; Brady AF; Miller C; Henderson A; Donaldson A; Murray A; Brewer C; Pottinger C; Evans DG; Eccles D; ; Lalloo F; Gregory H; Cook J; Eason J; Adlard J; Barwell J; Ong KR; Walker L; Izatt L; Side LE; Kennedy MJ; Tischkowitz M; Rogers MT; Porteous ME; Morrison PJ; Eeles R; Davidson R; Snape K; Easton DF; Antoniou AC
Genet Med; 2018 Dec; 20(12):1575-1582. PubMed ID: 29565421
[TBL] [Abstract][Full Text] [Related]
40. Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks.
Wolfson M; Gribble S; Pashayan N; Easton DF; Antoniou AC; Lee A; van Katwyk S; Simard J
Genet Med; 2021 Nov; 23(11):2114-2121. PubMed ID: 34230637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
